Home
DNLI
DNLI News

Latest Denali Therapeutics Inc. (DNLI) News on September 5, 2025

Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report?

Zacks

3 months ago

Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report?

MT Newswires

4 months ago

B. Riley Adjusts Denali Therapeutics Price Target to $30 From $35, Maintains Buy Rating

MT Newswires

4 months ago

Deutsche Bank Adjusts Denali Therapeutics Price Target to $28 From $29, Maintains Buy Rating

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Simply Wall St.

4 months ago

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus

Zacks

4 months ago

Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus

Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

GlobeNewswire

4 months ago

Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates

Zacks

4 months ago

5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates

MT Newswires

4 months ago

Top Premarket Decliners

DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up

Zacks

5 months ago

DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up

MT Newswires

5 months ago

Denali Therapeutics Files Application for Accelerated Approval of Hunter Syndrome Treatment; Shares Up

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

GlobeNewswire

5 months ago

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

Why You Shouldn't Bet Against Denali (DNLI) Stock

Zacks

6 months ago

Why You Shouldn't Bet Against Denali (DNLI) Stock

MT Newswires

6 months ago

B. Riley Trims Price Target on Denali Therapeutics to $35 From $38, Keeps Buy Rating

Denali Therapeutics price target lowered to $42 from $50 at Oppenheimer

TipRanks

6 months ago

Denali Therapeutics price target lowered to $42 from $50 at Oppenheimer

Is Denali Therapeutics Inc. (DNLI) Among Jeff Bezos’ Investments in 2025?

Insider Monkey

6 months ago

Is Denali Therapeutics Inc. (DNLI) Among Jeff Bezos’ Investments in 2025?

MT Newswires

6 months ago

Oppenheimer Adjusts Denali Therapeutics Price Target to $42 From $50, Maintains Outperform Rating

MT Newswires

6 months ago

Deutsche Bank Adjusts Denali Therapeutics Price Target to $29 From $31, Maintains Buy Rating

Denali Q4 Earnings Beat Estimates, Hunter Syndrome Drug in Focus

Zacks

6 months ago

Denali Q4 Earnings Beat Estimates, Hunter Syndrome Drug in Focus

MT Newswires

6 months ago

Wedbush Adjusts Price Target on Denali Therapeutics to $32 From $33, Maintains Outperform Rating

Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

GlobeNewswire

6 months ago

Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

MT Newswires

7 months ago

Deutsche Bank Initiates Coverage on Denali Therapeutics With Buy Rating, $31 Price Target

DNLI Reports Upbeat Longer-Term Data From Hunter Syndrome Study

Zacks

7 months ago

DNLI Reports Upbeat Longer-Term Data From Hunter Syndrome Study

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

GlobeNewswire

7 months ago

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™

GlobeNewswire

7 months ago

Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™

Denali Gains 26.6% in a Year: How Should You Play the Stock?

Zacks

7 months ago

Denali Gains 26.6% in a Year: How Should You Play the Stock?

Why Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside Potential

Insider Monkey

8 months ago

Why Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside Potential

Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

GlobeNewswire

8 months ago

Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation

Zacks

8 months ago

DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation

MT Newswires

8 months ago

Denali Gets FDA Breakthrough Therapy Designation for Hunter Syndrome Treatment

Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

GlobeNewswire

8 months ago

Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

Denali Therapeutics price target lowered to $32 from $35 at BTIG

TipRanks

8 months ago

Denali Therapeutics price target lowered to $32 from $35 at BTIG

These Stocks Moved the Most Today: Nvidia, Micron, Aurora Innovation, Tesla, Carvana, Moderna, Palantir, and More

Barrons.com

8 months ago

These Stocks Moved the Most Today: Nvidia, Micron, Aurora Innovation, Tesla, Carvana, Moderna, Palantir, and More

Denali Reverses Its Fortunes With 'Too Early' Miss In ALS Treatment

Investor's Business Daily

8 months ago

Denali Reverses Its Fortunes With 'Too Early' Miss In ALS Treatment

Denali's ALS Study Fails to Meet Primary and Secondary Endpoints

Zacks

8 months ago

Denali's ALS Study Fails to Meet Primary and Secondary Endpoints

Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected

Benzinga

8 months ago

Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected

Denali Therapeutics’ ALS therapy fails to meet primary endpoint in Phase II/III trial

Clinical Trials Arena

8 months ago

Denali Therapeutics’ ALS therapy fails to meet primary endpoint in Phase II/III trial

Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet.

Investor's Business Daily

8 months ago

Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet.

These Stocks Are Moving the Most Today: Nvidia, Micron, Uber, Aurora Innovation, Carvana, Moderna, Getty Images, and More

Barrons.com

8 months ago

These Stocks Are Moving the Most Today: Nvidia, Micron, Uber, Aurora Innovation, Carvana, Moderna, Getty Images, and More

MT Newswires

8 months ago

Baird Initiates Denali Therapeutics at Outperform With $31 Price Target

MT Newswires

8 months ago

Denali Therapeutics Trial of Potential ALS Treatment Misses Primary, Secondary Endpoints; Shares Fall After Hours

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

GlobeNewswire

8 months ago

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic

Benzinga

8 months ago

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic

Denali Therapeutics upgraded to Buy from Hold at Stifel

TipRanks

9 months ago

Denali Therapeutics upgraded to Buy from Hold at Stifel

MT Newswires

9 months ago

Stifel Nicolaus Upgrades Denali Therapeutics to Buy From Hold, Raises Price Target to $37 From $28

Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?

Zacks

9 months ago

Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?

Denali Starts Dosing in Phase II Parkinson's Disease Study

Zacks

9 months ago

Denali Starts Dosing in Phase II Parkinson's Disease Study

Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease

GlobeNewswire

9 months ago

Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease

MT Newswires

9 months ago

B. Riley Raises Price Target on Denali Therapeutics to $38 From $33, Keeps Buy Rating

We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely

Simply Wall St.

10 months ago

We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely

MT Newswires

10 months ago

Denali Therapeutics Insider Sold Shares Worth $1,932,665, According to a Recent SEC Filing

Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging

Zacks

10 months ago

Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging

Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

GlobeNewswire

10 months ago

Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Analysts Estimate Arcus Biosciences, Inc. (RCUS) to Report a Decline in Earnings: What to Look Out for

Zacks

10 months ago

Analysts Estimate Arcus Biosciences, Inc. (RCUS) to Report a Decline in Earnings: What to Look Out for

Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Zacks

10 months ago

Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

MT Newswires

10 months ago

Denali Therapeutics Insider Sold Shares Worth $1,107,600, According to a Recent SEC Filing

Denali Therapeutics Inc. (DNLI): Jeff Bezos Is Buying This Stock Now

Insider Monkey

a year ago

Denali Therapeutics Inc. (DNLI): Jeff Bezos Is Buying This Stock Now

Strength Seen in Voyager Therapeutics (VYGR): Can Its 17.5% Jump Turn into More Strength?

Zacks

a year ago

Strength Seen in Voyager Therapeutics (VYGR): Can Its 17.5% Jump Turn into More Strength?

MT Newswires

a year ago

UBS Adjusts Denali Therapeutics Price Target to $46 From $32, Maintains Buy Rating

Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength?

Zacks

a year ago

Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength?

Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report?

Zacks

a year ago

Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report?

Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound?

Zacks

a year ago

Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound?

Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug

Zacks

a year ago

Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug

Why Is BioMarin (BMRN) Up 5.4% Since Last Earnings Report?

Zacks

a year ago

Why Is BioMarin (BMRN) Up 5.4% Since Last Earnings Report?

High-dose Spinraza meets study goal; Top Dyne executives exit

BioPharma Dive

a year ago

High-dose Spinraza meets study goal; Top Dyne executives exit

MT Newswires

a year ago

Wedbush Adjusts Price Target on Denali Therapeutics to $27 From $26, Maintains Outperform Rating

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)

GlobeNewswire

a year ago

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)

Denali Therapeutics (NASDAQ:DNLI) shareholders are up 3.4% this past week, but still in the red over the last three years

Simply Wall St.

a year ago

Denali Therapeutics (NASDAQ:DNLI) shareholders are up 3.4% this past week, but still in the red over the last three years

MT Newswires

a year ago

Denali Therapeutics Insider Sold Shares Worth $549,928, According to a Recent SEC Filing

Genetic testing in Parkinson’s disease patients: a standard of care imperative?

Medical Device Network

a year ago

Genetic testing in Parkinson’s disease patients: a standard of care imperative?

Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration

GlobeNewswire

a year ago

Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration

Wall Street Analysts Believe Denali Therapeutics (DNLI) Could Rally 79.62%: Here's is How to Trade

Zacks

a year ago

Wall Street Analysts Believe Denali Therapeutics (DNLI) Could Rally 79.62%: Here's is How to Trade

MT Newswires

a year ago

B. Riley Adjusts Price Target on Denali Therapeutics to $33 From $36, Maintain Buy Rating

MT Newswires

a year ago

Wedbush Adjusts Denali Therapeutics' PT to $26 From $30, Keeps Outperform Rating

MT Newswires

a year ago

Denali Therapeutics Shares Fall After Swing to Q2 Net Loss

Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

GlobeNewswire

a year ago

Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar?

Zacks

a year ago

Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar?

Denali Therapeutics Stock Gets Technical Rating Upgrade

Investor's Business Daily

a year ago

Denali Therapeutics Stock Gets Technical Rating Upgrade

Denali (DNLI) Outperforms Industry in 3 Months: Here's Why

Zacks

a year ago

Denali (DNLI) Outperforms Industry in 3 Months: Here's Why

Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last?

Zacks

a year ago

Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last?

Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report?

Zacks

a year ago

Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report?

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Simply Wall St.

a year ago

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report?

Zacks

a year ago

Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report?

Denali's (DNLI) Candidate Selected for FDA's START Pilot Program

Zacks

a year ago

Denali's (DNLI) Candidate Selected for FDA's START Pilot Program

MT Newswires

a year ago

Denali Therapeutics' Enzyme Replacement Therapy Picked for FDA's START Pilot Program; Shares Rise

Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies

GlobeNewswire

a year ago

Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies

The Consensus EPS Estimates For Denali Therapeutics Inc. (NASDAQ:DNLI) Just Fell Dramatically

Simply Wall St.

a year ago

The Consensus EPS Estimates For Denali Therapeutics Inc. (NASDAQ:DNLI) Just Fell Dramatically

Denali Therapeutics First Quarter 2024 Earnings: US$0.68 loss per share (vs US$0.80 loss in 1Q 2023)

Simply Wall St.

a year ago

Denali Therapeutics First Quarter 2024 Earnings: US$0.68 loss per share (vs US$0.80 loss in 1Q 2023)

MT Newswires

a year ago

Stifel Adjusts Price Target on Denali Therapeutics to $22 From $26, Maintains Hold Rating

MT Newswires

a year ago

Wedbush Adjusts Denali Therapeutics' Price Target to $30 From $31, Keeps Outperform Rating

Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus

Zacks

a year ago

Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus

GuruFocus.com

a year ago

Denali Therapeutics Q1 2024 Earnings: Misses Revenue Estimates Amid Strategic Shifts

Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

GlobeNewswire

a year ago

Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

GlobeNewswire

a year ago

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Is There An Opportunity With Denali Therapeutics Inc.'s (NASDAQ:DNLI) 50% Undervaluation?

Simply Wall St.

a year ago

Is There An Opportunity With Denali Therapeutics Inc.'s (NASDAQ:DNLI) 50% Undervaluation?

Why Denali Therapeutics (DNLI) Stock Might be a Great Pick

Zacks

a year ago

Why Denali Therapeutics (DNLI) Stock Might be a Great Pick

Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?

Zacks

a year ago

Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?

Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?

Zacks

a year ago

Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?

Further weakness as Denali Therapeutics (NASDAQ:DNLI) drops 7.4% this week, taking three-year losses to 67%

Simply Wall St.

a year ago

Further weakness as Denali Therapeutics (NASDAQ:DNLI) drops 7.4% this week, taking three-year losses to 67%

Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up

Zacks

2 years ago

Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up

Denali Therapeutics Inc (DNLI) Reports Full Year and Q4 2023 Financial Results

GuruFocus.com

2 years ago

Denali Therapeutics Inc (DNLI) Reports Full Year and Q4 2023 Financial Results

Share on Social Networks: